Perioperative Reduction of Inapparent Myocardial Injury
PRIME
Effect of Remote Ischemic Preconditioning on Subclinical Myocardial Injury in Major Abdominal Surgery: a Randomised Controlled Trial
1 other identifier
interventional
84
1 country
1
Brief Summary
Recent data suggests that subclinical myocardial injury occurs in patients undergoing major abdominal surgery, and the degree of damage is proportionally linked to morbidity and mortality in the short and medium terms. Therefore, new methods of limiting myocardial damage are urgently needed. Ischemic preconditioning is a phenomenon whereby a brief non-lethal ischemia-reperfusion stimulus gives a protective effect to further ischemic insults. In remote ischemic preconditioning (RIPC), this initial stimulus is carried out away from the region of interest, normally a limb. In meta-analysed syntheses the effect size of RIPC in reducing cardiac damage during bypass grafting, as characterised by troponin release, seems to be about 35%. The PRIME Study will assess the value of RIPC in reducing subclinical myocardial injury in patients undergoing major abdominal surgery. Post-operative troponin release will be used as a surrogate marker of myocardial damage. There is no good data on which to build a reliable sample size calculation, therefore we estimated samples sizes using supplementary data from the recent VISION study. The investigators intend to build a clinically powered study from the results of this study. Study design will be by single-centre single-blind randomised control trial. Allocation will be 1:1. All treatments will be carried after induction of anaesthesia, prior to surgery. In the RIPC-treatment group, a blood pressure cuff inflated on an upper limb to 200mmHg for 5 minutes, and then deflated for 5 minutes, repeated in three cycles. In the control group, the blood pressure cuff will not be inflated, but the patient will remain under anaesthesia for the same amount of time. Primary endpoint will be peak post-operative 5th generation hs-TnT (highly sensitive Troponin-T, ng/ml). Secondary endpoint will be hs-TnT area-under-the-curve, major adverse cardiovascular events, serious surgical complications, non-cardiovascular death, quality of life, and length of stay.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2013
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 7, 2013
CompletedFirst Posted
Study publicly available on registry
May 10, 2013
CompletedStudy Start
First participant enrolled
June 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2017
CompletedAugust 31, 2017
March 1, 2016
2.8 years
May 7, 2013
August 29, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Peak post-operative troponin (ng/L)
At 6-12, 24, 48, 72h
Secondary Outcomes (4)
Any major adverse cardiovascular events
30 days
Any serious surgical complications
30 days
Area-under-the-curve post-operative troponin (ng/L)
72 hours
Positive post-operative troponin (binary endpoint, >20ng/L)
72 hours
Study Arms (2)
Intervention
ACTIVE COMPARATORPatients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
Control
SHAM COMPARATORPatients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
Interventions
Eligibility Criteria
You may qualify if:
- is ≥ 45 years old;
- is undergoing elective major colorectal or upper GI surgery.
You may not qualify if:
- Diabetic patients that are taking glibenclamide medication
- Patients with upper limb peripheral vascular disease, including those with arteriovenous fistula for dialysis
- Untreated hypertension (defined as two or more readings \>180mmHg systolic on admission for surgery)
- Current participation in any study investigating troponin levels or ischaemic preconditioning
- Unable or lacks capacity to give informed consent to participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Berkshire Hospital
Reading, Berks, RM7 0AG, United Kingdom
Related Publications (1)
Antonowicz SS, Cavallaro D, Jacques N, Brown A, Wiggins T, Haddow JB, Kapila A, Coull D, Walden A. Remote ischemic preconditioning for cardioprotection in elective inpatient abdominal surgery - a randomized controlled trial. BMC Anesthesiol. 2018 Jun 26;18(1):76. doi: 10.1186/s12871-018-0524-6.
PMID: 29945555DERIVED
Study Officials
- STUDY DIRECTOR
Andrew Walden, MBBS PhD MRCP
Royal Berkshire Hospitals
- PRINCIPAL INVESTIGATOR
Stefan S Antonowicz, MBChB MRCS
Royal berkshire Hospitals
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 7, 2013
First Posted
May 10, 2013
Study Start
June 1, 2013
Primary Completion
March 1, 2016
Study Completion
March 1, 2017
Last Updated
August 31, 2017
Record last verified: 2016-03